Page 7 - Illustrated Pathology of the Bone Marrow

130 Post-therapy bone marrow changes
recurrence of disease or metastasis, or it may be sec-
ondary to non-neoplastic sequelae of the therapy. These
secondary causes would be similar to the cause of marrow
fibrosis in any marrow (McCarthy, 1985), such as fibrosis
related to renal osteodystrophy, hypo- or hyperparathy-
roidism, or vitamin D deficiency. Patchy areas of fibro-
sis are also seen with bone marrow involvement by mast
cell disease (Horny et al., 1985), which may accompany
other hematologic malignancies at diagnosis or relapse (see
Chapter 9).
REFERENCES
Arber, D. A. (2006). Evaluation of the post-therapy bone marrow. In
Diagnostic Hematopathology, ed. E. S. Jaffe, N. L. Harris, & J. W.
Vardiman. New York, NY: Harcourt.
Armitage, J. O. (1998). Emerging applications of recombinant
human granulocyte–macrophage colony-stimulating factor.
Blood, 92, 4491–508.
Beham-Schmid, C., Apfelbeck, U., Sill, H., et al. (2002). Treatment of
chronic myelogenous leukemia with the tyrosine kinase inhibitor
STI571 results in marked regression of bone marrow fibrosis.
Blood, 99, 381–3.
Braziel, R. M., Launder, T. M., Druker, B. J., et al. (2002). Hema-
topathologic and cytogenetic findings in imatinib mesylate-
treated chronic myelogenous leukemia patients: 14 months’
experience. Blood, 100, 435–41.
Campbell, L. J., Maher, D., W., Tay, D. L., et al. (1992). Marrow
proliferation and the appearance of giant neutrophils in
response to recombinant human granulocyte colony stimulat-
ing factor (rhG-CSF). British Journal of Haematology, 80, 298–
304.
Cheson, B. D., Bennett, J. M., Kopecky, K. J., et al. (2003). Revised
recommendations of the International Working Group for diag-
nosis, standardization of response criteria, treatment outcomes,
and reporting standards for therapeutic trials in acute myeloid
leukemia. Journal of Clinical Oncology, 21, 4642–9.
Dreosti, L. M., Bezwoda, W., & Gunter, K. (1994). Bone marrow
necrosis following ALL-trans retinoic acid therapy for acute
promyelocytic leukaemia. Leukemia and Lymphoma, 13, 353–6.
Facchetti, F., Tironi, A., Marocolo, D., et al. (1997). Histopatho-
logical changes in bone marrow biopsies from patients with
chronic myeloid leukaemia after treatment with recombinant
alpha-interferon. Histopathology, 31, 3–11.
Harris, A. C., Todd, W. M., Hackney, M. H., & Ben-Ezra, J.
(1994). Bone marrow changes associated with recombinant
granulocyte–macrophage and granulocyte colony-stimulating
factors: discrimination of granulocytic regeneration. Archives of
Pathology and Laboratory Medicine, 118, 624–9.
Hasserjian, R. P., Boecklin, F., Parker, S., et al. (2002). ST1571 (ima- Michelson, J. D., Gornet, M., Codd, T., Torres, J., Lanighan, K., &
tinib mesylate) reduces bone marrow cellularity and normal-
izes morphologic features irrespective of cytogenetic response.
American Journal of Clinical Pathology, 117, 360–7.
Downloaded from https://www.cambridge.org/core. University College London (UCL), on 28 Apr 2018 at 18:26:18, subject to the Cambridge Core terms of use, available at
https://www.cambridge.org/core/terms. https://doi.org/10.1017/CCBaOm97b8r0i5d1g1e54B35o3o1k.0s15Online © Cambridge University Press, 2009
Horny, H. P., Parwaresch, M. R., & Lennert, K., (1985). Bone mar-
row findings in systemic mastocytosis. Human Pathology, 16,
808–14.
Innes, D. J. Jr., Hess, C. E., Bertholf, M. F., & Wade, P. (1987).
Promyelocyte morphology: differentiation of acute promyelo-
cytic leukemia from benign myeloid proliferations. American
Journal of Clinical Pathology, 88, 725–9.
Islam, A., Catovsky, D., Goldman, J. M., & Galton, D. A. (1984). Bone
marrow fibre content in acute myeloid leukaemia before and
after treatment. Journal of Clinical Pathology, 37, 1259–63.
Janssens, A. M., Offner, F. C., & Van Hove, W. Z. (2000). Bone marrow
necrosis. Cancer, 88, 1769–80.
Johnston, R. E., Geretti, A. M., Prentice, H. G., et al. (1999). HHV-6-
related secondary graft failure following allogeneic bone marrow
transplantation. British Journal of Haematology, 105, 1041–3.
Kantarjian, H. M., Keating, M. J., McCredie, K. B., et al. (1985). A
characteristic pattern of leukemic cell differentiation without
cytoreduction during remission induction in acute promyelo-
cytic leukemia. Journal of Clinical Oncology, 3, 793–8.
Kantarjian, H., Sawyers, C., Hochhau, A., et al. (2002). Hemato-
logic and cytogenetic responses to imatinib mesylate in chronic
myelogenous leukemia. New England Journal of Medicine, 346,
645–52.
Katayama, Y., Deguchi, S., Shinagawa, K., et al. (1998). Bone mar-
row necrosis in a patient with acute myeloblastic leukemia dur-
ing administration of G-CSF and rapid hematologic recovery
after allotransplantation of peripheral blood stem cells. Amer-
ican Journal of Hematology, 57, 238–40.
Kerrigan, D. P., Castillo, A., Foucar, K., Townsend, K., & Neidhart,
J. (1989). Peripheral blood morphologic changes after high-dose
antineoplastic chemotherapy and recombinant human granulo-
cyte colony-stimulating factor administration. American Journal
of Clinical Pathology, 92, 280–5.
Luppi, M., Barozzi, P., Schulz, T. F., et al. (2000). Bone marrow failure
associated with human herpesvirus 8 infection after transplan-
tation. New England Journal of Medicine, 343, 1378–85.
Macon, W. R., Tham, K. T., Greer, J. P., & Wolff, S. N. (1995). Ringed
sideroblasts: a frequent observation after bone marrow trans-
plantation. Modern Pathology, 8, 782–5.
McCarthy, D. M. (1985). Fibrosis of the bone marrow: content and
causes. British Journal of Haematology, 59, 1–7.
Meyerson, H. J., Farhi, D. C., & Rosenthal, N. S. (1998). Transient
increase in blasts mimicking acute leukemia and progressing
myelodysplasia in patients receiving growth factor. American
Journal of Clinical Pathology, 109, 675–81.
Jones, R. (1993). Bone morphology after bone marrow transplan-
tation for Hodgkin’s and non-Hodgkin’s lymphoma. Experimen-
tal Hematology, 21, 475–82.
Orazi, A., Cattoretti, G., Schiro, R., et al. (1992). Recombinant
human interleukin-3 and recombinant human granulocyte–
macrophage colony-stimulating factor administered in vivo after
high-dose cyclophosphamide cancer chemotherapy: effect on
hematopoiesis and microenvironment in human bone marrow.
Blood, 79, 2610–19.